Skip to main content
. 2012 Feb;25(1):37–44. doi: 10.1089/vim.2011.0044

FIG. 2.

FIG. 2.

Distribution of natural killer (NK) CD56neg cells in HIV-1-seropositive vaccinated and placebo patients. A rise in NK CD56neg cells can be observed from the 24th week to the end of the study period in HIV-1-immunized patients. The values were statistically significant at the 24th week of treatment (p=0.013).